We are officially in the last four months of 2026 - the last calendar year without an FDA approved psychedelic on the market.
If you are interested in this space both of these players have strong potential to trigger DEA rescheduling of the two most consequential classical
This is likely if $CMPS completes their final NDA submission sometime in October. With the National Priority Voucher they received in April shortening FDA review windows down to just 1-2 months 2027 could start with a bang.
Commercial sales likely start sometime between
$DFTX sitting at nearly $1.1B in cash & cash equivalents with runway expected to 2030 based on today’s 2026 Q2 earnings report. No other psychedelic-focused company has ever had so much cash on their balance sheet.
Considering Definium is likely 2nd/3rd to market with potential
